Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on May 27, 2025
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
·
May 27, 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’ …
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
May 27, 2025
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop …
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
GlobeNewswire
·
May 27, 2025
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery …
GridCARE Launches with a Mission to Eliminate AI’s Biggest Bottleneck: Immediate Access to Power
GlobeNewswire
·
May 27, 2025
REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- GridCARE, a new company powering the AI revolution, emerged from stealth today. The company has closed a highly oversubscribed $13.5 million Seed financing round led by Xora, a deep technology venture …
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to …
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
GlobeNewswire
·
May 27, 2025
ROSCREA, Ireland and FREIBURG, Germany, May 27, 2025 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) …
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced an upcoming presentation at the …
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
GlobeNewswire
·
May 27, 2025
LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the publication of preclinical proof-of-concept data for FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease in Molecular Therapy, the flagship …
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the …
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 27, 2025
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewswire
·
May 27, 2025
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
authID Announces its 2025 Board of Directors Nominees Ahead of Annual Meeting
GlobeNewswire
·
May 27, 2025
Highly Qualified New Board Nominees Will Strengthen authID’s mission to Drive Growth and Value Creation for Shareholders 2025 Annual Meeting to be Held on June 26, 2025 DENVER, May 27, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID)(“authID” or the “ …
Emory Healthcare Researchers Use Dynamic Digital Radiography to Compare Shoulder Improvement of Two Surgical Interventions for Massive Irreparable Rotator Cuff Tears
GlobeNewswire
·
May 27, 2025
WAYNE, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., congratulates Emory Healthcare researchers on the publication of a new study using Dynamic Digital Radiography (DDR) to compare shoulder biomechanics in patients after …
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 27, 2025
- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) …
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
GlobeNewswire
·
May 27, 2025
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May …
DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal
GlobeNewswire
·
May 27, 2025
DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today …
Theriva™ Biologics anuncia la presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en ASCO 2025 y la reunión de investigadores para revisar los datos preliminares del ensayo VIRAGE de Fase 2b del VCN-01 para el…
GlobeNewswire
·
May 27, 2025
- Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión de pósteres en la reunión anual de la Sociedad Americana de Oncología Clínica ( …
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
GlobeNewswire
·
May 27, 2025
Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting SYDNEY, …
Reflect Scientific, Inc. Announces Strategic Cost-Cutting Initiative to Reduce SG&A Expenses by Up to 35% in 2025
GlobeNewswire
·
May 27, 2025
OREM, Utah, May 27, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leading innovator in cryogenic cooling technologies, today announced a comprehensive initiative to reduce Selling, General …
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
GlobeNewswire
·
May 27, 2025
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, …